Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
News|Articles|October 18, 2013
Penn Pharma Partners With GEA Pharma To Open New Facility
Author(s)Melanie Sena
Penn Pharma partners with GEA Pharma to open a new facility for the development and manufacture of oncology drugs.
Advertisement
Penn Pharma, a provider of integrated drug-development, clinical-trial supply, and manufacturing services, has partnered with
The new 15,000 ft2 site offers a geometrically scalable dispensing, granulation, and blending process from powder to capsules. Highly contained equipment trains were designed to minimize the need for personal protective equipment and reduce the use of isolators to a minimum.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement